Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative, patient-friendly medicines using its proprietary oral delivery technologies. The company operates within the biopharmaceutical and central nervous system (CNS) therapeutic areas, with a primary emphasis on epilepsy and other neurological conditions. Its core value proposition centers on replacing traditional pill-based therapies with orally administered alternatives designed to improve patient adherence and outcomes.
The company’s primary revenue drivers include its proprietary drug products and collaborative manufacturing and licensing arrangements. Sympazan® (clobazam) oral film is its key commercial product, approved for the treatment of seizures associated with Lennox-Gastaut syndrome. Aquestive was founded in 2004 and originally operated under the name MonoSol Rx, reflecting its focus on oral thin-film technology. The company rebranded as Aquestive Therapeutics in 2018 following its public listing and expanded strategic focus on proprietary CNS drug development.
Business Operations
Aquestive operates through integrated development, manufacturing, and commercialization activities, with revenue generated from both product sales and strategic partnerships. Its business is centered on proprietary drug candidates developed using its PharmFilm® and Adhesive Film drug delivery platforms, which enable non-invasive oral administration without water. Commercial revenue is primarily derived from Sympazan®, while additional income has historically included contract manufacturing and licensing arrangements.
Operations are primarily based in the United States, with manufacturing conducted at company-controlled facilities. The company has engaged in partnerships with pharmaceutical companies for development, manufacturing, and commercialization, including historical collaborations with Novartis AG and Indivior PLC. These relationships have supported both technology validation and non-dilutive revenue generation, although the company’s current strategy emphasizes proprietary product commercialization.
Strategic Position & Investments
Aquestive’s strategic direction is focused on advancing a pipeline of proprietary CNS and epilepsy therapies while leveraging its oral film technology to address unmet medical needs. Key growth initiatives include the development of Libervant™ (diazepam) buccal film for seizure clusters and Anaphylm™ (epinephrine) oral film for severe allergic reactions, both designed to offer alternatives to injectable or rectal therapies.
The company has invested significantly in internal research and development rather than large-scale acquisitions, prioritizing organic growth of its pipeline. Its portfolio also includes early-stage candidates targeting Parkinson’s disease and other neurological disorders. Strategic investments are directed toward regulatory approvals, clinical trials, and manufacturing scalability to support future commercialization.
Geographic Footprint
Aquestive Therapeutics is headquartered in the United States, with its principal executive offices and manufacturing operations located in New Jersey. The company’s commercial focus is primarily on the U.S. market, where its approved and pipeline products are intended for distribution through specialty pharmaceutical channels.
Internationally, Aquestive’s presence has been shaped more by licensing and partnership arrangements than by direct operations. Its technologies and products have had exposure to European and other international markets through partners, but the company does not currently maintain a broad global commercial infrastructure. Its strategic emphasis remains on expanding U.S. market penetration while selectively pursuing international opportunities through collaborations.
Leadership & Governance
Aquestive is led by an experienced management team with backgrounds in pharmaceuticals, biotechnology, and drug commercialization. The leadership team emphasizes a strategy centered on patient-centric innovation, disciplined capital allocation, and the advancement of differentiated therapies for CNS conditions. Governance is overseen by a board of directors with expertise in life sciences, finance, and regulatory affairs.
Key executives include:
- Daniel Barber – President and Chief Executive Officer
- Eric Dilly – Chief Financial Officer
- Michael J. Driscoll – Chief Operating Officer
- David J. Baker – Chief Legal Officer and Corporate Secretary
- Rey R. Fennell – Chief Commercial Officer
The leadership team’s stated vision focuses on transforming the treatment experience for patients who struggle with conventional oral or injectable medications, while building long-term shareholder value through proprietary product commercialization.